PCM
PEAR

Penserra Capital Management’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Penserra Capital Management’s Portfolio PEAR Stock Details PEAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-3,379
Closed -$5K – 1366
2022
Q2 		$5K Sell
3,379
-1,320
-28% -$5.16K ﹤0.01% 1354
2022
Q1 		$23K Sell
4,699
-1,353
-22% -$6.15K ﹤0.01% 1229
2021
Q4 		$37K Buy
+6,052
New +$54K ﹤0.01% 1102

Other funds holding PEAR

Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SGA
SB Global Advisers London, United Kingdom $861M AUM 71.72% 1-Year Est. Return
AV
Arboretum Ventures Ann Arbor, Michigan $1.72M AUM 82.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TAA
TB Alternative Assets Grand Cayman, Cayman Islands $623M AUM 154.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PT
Palantir Technologies Denver, Colorado $9.72M AUM 6.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Penserra Capital Management's PEAR Position: Q3 2022 in Review

Penserra Capital Management sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q3 2022, closing a stake of 3,379 shares — an estimated $5K sold.

Penserra Capital Management first reported a position in PEAR in Q4 2021 and held it in 3 quarters. The position peaked at $37K in Q4 2021. 60 funds tracked by Wall St. Rank hold PEAR as of Q3 2022.

  • Penserra Capital Management reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q3 2022 after selling out during the quarter.
  • Penserra Capital Management sold 3,379 Pear Therapeutics, Inc. Class A Common Stock shares in Q3 2022, an estimated $5K.
  • Penserra Capital Management first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q4 2021 and held it in 3 quarters.
  • Penserra Capital Management's Pear Therapeutics, Inc. Class A Common Stock position peaked at $37K in Q4 2021.
  • 60 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q3 2022.

Based on Penserra Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.